Physician profile
Edward A Dominguez
NPI 1598765828
$121,010.07
in general payments reported to CMS, 2019-2025
36 companies · $6,330 in 2025
The $6,330 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $12K · 2021: $8,241 · 2022: $3,589 · 2023: $1,330 · 2024: $16K · 2025: $6,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,918 · Honoraria: $6,084 · Food and Beverage: $3,762 · Consulting Fee: $3,322 · Travel and Lodging: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,917.75 |
| Honoraria | $6,084.00 |
| Food and Beverage | $3,761.98 |
| Consulting Fee | $3,322.00 |
| Travel and Lodging | $2,429.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37,595.67 | 2019 | |
| Sanofi Pasteur INC. | $27,176.90 | 2019-2024 | |
| Tetraphase Pharmaceuticals, INC. | $26,499.92 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $11,552.57 | 2021-2024 | Xacduro |
| Melinta Therapeutics, LLC | $10,036.56 | 2024-2025 | Rezzayo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,770.72 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $1,336.33 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $672.11 | 2019-2025 | Ocaliva |
| Abbvie INC. | $572.02 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $500.00 | 2020 | |
| Eisai INC. | $363.79 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $355.14 | 2022-2025 | Livtencity |
| Madrigal Pharmaceuticals | $228.46 | 2025 | Rezdiffra |
| Eurofins Viracor, LLC | $183.24 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $166.70 | 2022-2025 | Nuzyra |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $126.30 | 2020-2025 | Cresemba |
| Viiv Healthcare Company | $111.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.86 | 2022 | |
| Merck Sharp & Dohme LLC | $85.05 | 2019-2025 | Prevymis, Zerbaxa, Dificid |
| Hemosonics LLC | $65.82 | 2023 | Quantra Qplus System |
| Mirum Pharmaceuticals, INC. | $59.66 | 2023-2025 | Livmarli, Cholbam, Chenodal |
| Orphalan INC | $56.96 | 2024-2025 | Cuvrior |
| Alexion Pharmaceuticals, INC. | $56.60 | 2019-2025 | Ultomiris |
| Shionogi INC | $55.19 | 2019-2022 | |
| Dynavax Technologies Corporation | $54.31 | 2022-2024 | Heplisav-B |
| Laborie Medical Technologies Corp. | $37.68 | 2024 | Renovarp |
| Veloxis Pharmaceuticals, INC. | $27.77 | 2025 | Envarsus |
| Aimmune Therapeutics, INC. | $25.37 | 2025 | Vowst |
| Vbi Vaccine (Delaware) INC. | $24.94 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.46 | 2023 | Oxlumo |
| Ipsen Biopharmaceuticals, INC | $18.66 | 2024 | Bylvay |
| Exact Sciences Corporation | $18.02 | 2024 | |
| Novo Nordisk INC | $17.28 | 2025 | Wegovy |
| Pfizer INC. | $14.29 | 2022 | |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.